Spots Global Cancer Trial Database for postmenopausal
Every month we try and update this database with for postmenopausal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation | NCT00926315 | Breast Neoplasm... Postmenopausal ... | calcitriol Calcitriol | 40 Years - 70 Years | University of Sao Paulo General Hospital | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors | NCT01758146 | Breast Cancer | Tamoxifen Letrozole | 45 Years - 80 Years | PGIMER | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Exemestane-RAD001-Metformin | NCT01627067 | Breast Cancer | Everolimus Exemestane Metformin | 18 Years - | M.D. Anderson Cancer Center | |
| Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | NCT01484041 | Breast Cancer | Dovitinib Aromatase Inhib... | 18 Years - | Georgetown University | |
| Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide | NCT02502864 | Breast Cancer Breast Cancer F... | Standard of Car... Standard of Car... Function Assess... | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT00329940 | Breast Cancer | Letrozole | 18 Years - | Novartis | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors | NCT02235051 | Cancer Survivor Estrogen Recept... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Postmenopausal | exercise interv... laboratory biom... questionnaire a... quality-of-life... | 56 Years - | City of Hope Medical Center | |
| A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen | NCT01223833 | Breast Cancer Arthralgia | 18 Years - | Universitaire Ziekenhuizen KU Leuven | ||
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | NCT05054374 | Breast Cancer Breast Cancer S... HER2-negative B... Solid Carcinoma MEK1 Gene Mutat... MEK2 Gene Mutat... Metastatic Brea... | Mirdametinib Fulvestrant | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers | NCT05438303 | Healthy Volunte... | AZD9833 Midazolam Omeprazole Dabigatran Etex... Celecoxib | 50 Years - 70 Years | AstraZeneca | |
| Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | NCT00248170 | Breast Cancer | Letrozole Anastrozole | 33 Years - 96 Years | Novartis | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors | NCT04493333 | Vaginal Atrophy Postmenopausal ... Breast Cancer F... Long-term Survi... | Vaginal Dehydro... Vaginal Polycar... | 18 Years - 70 Years | University of Arkansas | |
| The Impact of Obesity and Obesity Treatments on Breast Cancer | NCT00933309 | Breast Cancer | Exemestane Avandamet | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers | NCT05438303 | Healthy Volunte... | AZD9833 Midazolam Omeprazole Dabigatran Etex... Celecoxib | 50 Years - 70 Years | AstraZeneca | |
| Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer | NCT02769104 | Neoadjuvant The... | Letrozole (Arom... AC*4-T*4 | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients | NCT02383030 | Metastatic Brea... | Fulvestrant | 18 Years - | Consorzio Oncotech | |
| Effect of Aromatase Inhibitors on Bones and Genes | NCT00603967 | Breast Cancer Postmenopausal | Dual x-ray abso... Blood draw Questionnaire | 40 Years - | Washington University School of Medicine | |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | NCT02894398 | Breast Cancer Hormone Recepto... Human Epidermal... | Palbociclib Letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | iOMEDICO AG | |
| Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer | NCT03324932 | Breast Cancer | Denosumab Injec... | 20 Years - | Kyoto Prefectural University of Medicine | |
| Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT00329940 | Breast Cancer | Letrozole | 18 Years - | Novartis | |
| Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | NCT00248170 | Breast Cancer | Letrozole Anastrozole | 33 Years - 96 Years | Novartis | |
| A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT01216176 | Breast Cancer | Anastrozole AZD0530 (saraca... Placebo | 18 Years - | University of Miami | |
| QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT00626106 | Breast Cancer Breast Tumors Metastatic Canc... | AMG 479 or plac... AMG 479 or plac... AMG 479 or plac... | 18 Years - | NantCell, Inc. | |
| Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | NCT00332852 | Breast Cancer | Letrozole | 18 Years - | Novartis | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Broccoli Sprout Extract in Treating Patients With Breast Cancer | NCT01753908 | Ductal Breast C... Ductal Breast C... Estrogen Recept... Estrogen Recept... Invasive Breast... Lobular Breast ... Postmenopausal Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... | Broccoli Sprout... Laboratory Biom... Pharmacological... Placebo | 21 Years - | Roswell Park Cancer Institute | |
| Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. | NCT00171340 | Bone Loss Breast Cancer | Zoledronic acid Letrozole | - | Novartis | |
| Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer | NCT00793546 | Advanced Breast... | Bosutinib exemestane Exemestane | 18 Years - | Pfizer | |
| Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) | NCT01635413 | Malignant Neopl... Postmenopausal | Exercise Interv... Exercise Interv... Exercise Interv... Questionnaire A... | 50 Years - 75 Years | OHSU Knight Cancer Institute | |
| Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer | NCT02769104 | Neoadjuvant The... | Letrozole (Arom... AC*4-T*4 | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | NCT01831076 | Breast Cancer Stage II Breast... Stage III Breas... | Exemestane Exemestane and ... | 50 Years - | University of Colorado, Denver | |
| Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors | NCT04493333 | Vaginal Atrophy Postmenopausal ... Breast Cancer F... Long-term Survi... | Vaginal Dehydro... Vaginal Polycar... | 18 Years - 70 Years | University of Arkansas | |
| Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | NCT00921115 | Invasive Breast... | Fulvestrant Anastrazole | 18 Years - | University of Kansas Medical Center | |
| Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer | NCT02769104 | Neoadjuvant The... | Letrozole (Arom... AC*4-T*4 | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Stellate Ganglion Block to Reduce Hot Flushes | NCT03756272 | Hot Flash Stellate Gangli... Postmenopausal Hot Flushes | Bupivacaine blo... Placebo ganglio... | 30 Years - 70 Years | Rijnstate Hospital | |
| Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation | NCT00926315 | Breast Neoplasm... Postmenopausal ... | calcitriol Calcitriol | 40 Years - 70 Years | University of Sao Paulo General Hospital | |
| Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer | NCT00201864 | Breast Cancer | Exemestane Fulvestrant | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | NCT02657928 | Estrogen Recept... Postmenopausal Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... | Laboratory Biom... Letrozole Ribociclib | 18 Years - | Mayo Clinic | |
| Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer | NCT02831582 | Arthralgia Breast Neoplasm... | Omega-3 Fatty A... Placebo | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer | NCT00338728 | Anatomic Stage ... Estrogen Recept... KIT Positive PDGFR Positive Postmenopausal Progesterone Re... Prognostic Stag... | Imatinib Mesyla... Letrozole | - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer | NCT02769104 | Neoadjuvant The... | Letrozole (Arom... AC*4-T*4 | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | NCT00332709 | Osteoporosis Postmenopausal | Letrozole Zoledronic acid | 18 Years - | Novartis | |
| Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors | NCT01758146 | Breast Cancer | Tamoxifen Letrozole | 45 Years - 80 Years | PGIMER | |
| Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer | NCT00816244 | Breast Cancer Postmenopausal | Atorvastatin | 18 Years - | Lund University Hospital | |
| Treatment of HPV Infection in Perimenopausal and Postmenopausal Women | NCT05863975 | HPV Infection | Human interfero... | 45 Years - 60 Years | Qianfoshan Hospital | |
| Glucose-Guided Eating Pilot | NCT05998460 | Postmenopausal Prediabetes Adolescent and ... | Glucose-Guided ... CGM only | 18 Years - | Georgetown University | |
| A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors | NCT02322853 | Postmenopausal Metastatic Brea... | Tamoxifen Ralimetinib (LY... | 18 Years - | Centre Francois Baclesse | |
| Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer | NCT00201864 | Breast Cancer | Exemestane Fulvestrant | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen | NCT00984399 | Atrophic Vagini... Breast Cancer | Vagifem® (vagin... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Effect of Aromatase Inhibitors on Bones and Genes | NCT00603967 | Breast Cancer Postmenopausal | Dual x-ray abso... Blood draw Questionnaire | 40 Years - | Washington University School of Medicine | |
| Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | NCT03180294 | Breast Carcinom... Cervical Carcin... Ovarian Carcino... Postmenopausal Uterine Corpus ... Vaginal Carcino... Vulvar Carcinom... | Bupropion 150 m... Placebo | 18 Years - | NRG Oncology | |
| Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | NCT03822468 | Breast Cancer | Ribociclib Anastrozole Letrozole Goserelin | 18 Years - | Novartis | |
| A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen | NCT01223833 | Breast Cancer Arthralgia | 18 Years - | Universitaire Ziekenhuizen KU Leuven | ||
| Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer | NCT00073073 | Breast Neoplasm... | Exemestane Calcium carbona... Vitamin D | - | Georgetown University | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| Effect of Aromatase Inhibitors on Bones and Genes | NCT00603967 | Breast Cancer Postmenopausal | Dual x-ray abso... Blood draw Questionnaire | 40 Years - | Washington University School of Medicine | |
| Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer | NCT01237327 | Metastatic Brea... | Megestrol aceta... exemestane (Aro... | - | Pfizer | |
| Stellate Ganglion Block to Reduce Hot Flushes | NCT03756272 | Hot Flash Stellate Gangli... Postmenopausal Hot Flushes | Bupivacaine blo... Placebo ganglio... | 30 Years - 70 Years | Rijnstate Hospital | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | NCT02095184 | Breast Cancer | Anastrozole Letrozole | 18 Years - | University of Maryland, Baltimore | |
| Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | NCT01484041 | Breast Cancer | Dovitinib Aromatase Inhib... | 18 Years - | Georgetown University | |
| Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer | NCT00816244 | Breast Cancer Postmenopausal | Atorvastatin | 18 Years - | Lund University Hospital | |
| A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | NCT00728949 | Metastatic Brea... | IMC-A12 (cixutu... tamoxifen Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Eli Lilly and Company | |
| Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors | NCT03953157 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Arthralgia Postmenopausal Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Dietary Interve... Exercise Interv... Questionnaire A... | - | Jonsson Comprehensive Cancer Center | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. | NCT02010021 | Breast Cancer | Letrozole | 18 Years - | Dartmouth-Hitchcock Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
